Merck & Co. Sales Rebates and Discounts decreased by 31.8% to $1.50B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 31.8%, from $2.20B to $1.50B. Over 5 years (FY 2020 to FY 2025), Sales Rebates and Discounts shows a downward trend with a -10.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to sales may indicate more aggressive pricing strategies or increased competitive pressure.
This metric represents the accrued liability for estimated rebates, volume discounts, and chargebacks owed to customers...
Highly prevalent in the pharmaceutical and retail sectors where complex pricing structures exist.
sales_rebates_and_discounts| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $2.60B | $2.70B | $2.30B | $2.20B | $1.50B |
| QoQ Change | — | +3.8% | -14.8% | -4.3% | -31.8% |
| YoY Change | — | +3.8% | -14.8% | -4.3% | -31.8% |